Investment Rating - The report maintains an "Outperform" rating for the following A-share targets: Jiangsu Heng Rui Medicine, Sichuan Kelun Pharmaceutical, Huadong Medicine, Jiangsu Nhwa Pharmaceutical, Xiamen Amoytop Biotech, Zhejiang Jingxin Pharmaceutical, Innovent Biologics, WuXi AppTec, Hangzhou Tigermed Consulting, Lepu Medical, MicroPort EP MedTech [5][36][8] - The report also maintains an "Outperform" rating for the following H-share targets: Hansoh Pharmaceutical Group, 3SBio, PATEO Biotech, Akeso, and related targets: Innovent Biologics, WuXi AppTec [8][36] Core Insights - The report continues to recommend the innovative drug and device industry and its supply chains, indicating a positive outlook for this sector [1][36] - In December 2025, the pharmaceutical sector underperformed the market, with the SW Pharmaceutical and Biological index falling by 4.1%, while the SHCOMP rose by 2.1%, ranking 26th among Shenwan primary industries [15][37] - The report highlights that the premium level of the pharmaceutical sector relative to all A-shares is currently at a normal level, with a relative premium rate of 63.2% as of the end of December 2025 [25][37] Summary by Sections A-Share Targets - The report includes a monthly portfolio of A-share targets that outperformed the pharmaceutical index, with a monthly average decline of 1.8% compared to the overall pharmaceutical index decline of 3.9% in December 2025 [11][36] - The top three stock gains in December 2025 were Luyan Pharma (+118.8%), CareRay Digital Medical Technology Co., Ltd. (+36.6%), and Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (+34.0%) [24][37] H-Share Targets - The report notes that the Hong Kong stock pharmaceutical sector also underperformed the market, with the Hang Seng Healthcare index falling by 9.5% and the Hong Kong Biological Technology index falling by 10.6% in December 2025 [26][38] U.S. Market Performance - In December 2025, the U.S. pharmaceutical sector underperformed the market, with the S&P 500 Healthcare Select Sector declining by 1.5% while the S&P 500 fell by only 0.1% [26][39]

Group 1 - The brain-computer interface sector experienced a strong surge on the first trading day of A-shares in 2026, with stocks like Botao Bio, Sino Medical, and Xiangyu Medical hitting the daily limit of 20% increase, leading to a 5.6% rise in the medical device ETF [1] - Elon Musk announced on social media that his brain-computer interface company Neuralink will begin "mass production" of brain-computer interface devices in 2026 [1] - In 2025, China approved 76 innovative drugs for market launch, significantly surpassing the 48 approved in 2024, marking a historical high [1] Group 2 - The medical device ETF (562600) rose by 5.65%, tracking the CSI All-Share Medical Device Index, with a high industry representation of 89% and a brain-computer interface content of 23.14%, outperforming other medical ETFs [1] - The Hang Seng Medical ETF (159892) increased by 6.07%, with a latest scale of 5.564 billion yuan, featuring top-weighted stocks such as BeiGene, WuXi Biologics, and CanSino Biologics [2] - The Hong Kong Stock Connect Medical ETF (520510) rose by 5.72%, leading the market in CXO concentration, with key stocks including WuXi Biologics, MicroPort, and JD Health [2]

Core Insights - The Hong Kong innovation drug sector has shown a significant recovery, with the Hang Seng Innovation Drug Index rising by 4.5% as of 14:00, driven by strong performances from key stocks such as InnoCare Pharma-B, which increased by over 10% [1] - Recent breakthroughs in innovative drug development include the approval of the first domestically developed CTLA-4 inhibitor, "Daboshu," by Innovent Biologics, and the approval of the TROP2 ADC "Trastuzumab Deruxtecan" for breast cancer by AstraZeneca and Daiichi Sankyo, enhancing the competitive landscape of ADCs [1] - The volume of business development (BD) transactions in innovative drugs continues to grow, with a record total authorization amount of $135.655 billion and 157 transactions in 2025, highlighting significant market activity [1] - Notable licensing deals include the $2 billion authorization of CBP-1018 by Tongyi Pharmaceutical and a $1.06 billion deal for the ADC drug SIM0613 by Ascletis, along with a collaboration exceeding $2 billion between Gossamer Bio and AstraZeneca for a pan-KRAS inhibitor [1] - Pacific Securities indicates that the pharmaceutical and biotechnology industry is entering a critical phase of innovation realization and global expansion, with a potential performance inflection point and valuation reshaping expected by 2026 [1] Industry Overview - The Hang Seng Innovation Drug Index is the first "pure" innovation drug index with 100% purity, focusing on leading companies in the Hong Kong innovation drug sector [2] - The E Fund Innovation Drug ETF (159316) is currently the only product tracking this index, providing investors with a streamlined way to capitalize on investment opportunities in the sector [2]

Group 1 - The core viewpoint of the news highlights a significant increase in the biopharmaceutical sector within the Hong Kong stock market, with the innovative drug ETF (159567) rising by 5.21% and achieving a trading volume exceeding 1.3 billion HKD [1] - The NextPharma database indicates that by December 31, 2025, the total transaction amount for China's innovative drug business development (BD) overseas authorization is projected to reach 135.655 billion USD (approximately 948.3 billion RMB), with an upfront payment of 7 billion USD and a total of 157 transactions, marking a historical high compared to 51.9 billion USD and 94 transactions in 2024 [1] - Southwest Securities predicts that the innovative drug sector will experience a surge starting in May 2025, driven by the 1.25 billion USD upfront payment for PD1/VEGR dual antibodies, leading to a bullish market for innovative drugs [1] Group 2 - The Hong Kong innovative drug ETF (159567) closely tracks the National Index for Hong Kong Stock Connect Innovative Drugs, featuring leading stocks such as BeiGene, Innovent Biologics, and 3SBio, with a notable inclusion of several AI-driven pharmaceutical leaders, indicating a high proportion of innovative drug companies [2] - The ETF is expected to exhibit high elasticity as the market for AI-enabled innovative drugs gains momentum [2]

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector is showing strong performance, with the Hong Kong Stock Connect Innovative Drug ETF (520880) experiencing a significant increase of 5.22% and a trading volume surge of nearly 200% compared to the previous trading day [1][7]. Group 1: ETF Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) covers 37 innovative drug research companies, with 36 stocks showing gains, including a rise of over 11% for InnoCare Pharma-B and over 8% for Kelun-B [1][7]. - Major weighted stocks such as Innovent Biologics, Rongchang Biopharmaceuticals, and BeiGene all increased by over 6% [1][7]. Group 2: Regulatory and Market Trends - According to the National Medical Products Administration, 76 innovative drugs are expected to be approved for market in China by 2025, a significant increase from 48 in 2024, marking a historical high [9][10]. - The domestic innovative drugs are particularly notable, accounting for 80.85% in chemical drugs and 91.30% in biological products [9][10]. Group 3: Market Opportunities - The total value of innovative drug licensing transactions in China is projected to exceed $130 billion in 2025, with over 150 transactions, both figures representing historical records and significant increases from 2024 [10]. - China's pipeline of new drugs currently holds a 30% share of the global total, ranking second worldwide [10]. Group 4: Investment Insights - Huafu Securities emphasizes that the long-term logic of pharmaceutical innovation remains unchanged, suggesting a positive outlook for innovative drugs in 2026 following a market adjustment in the second half of 2025 [10]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has unique advantages in asset allocation [10].

Group 1 - The core viewpoint of the news is that the A-share and Hong Kong markets are experiencing a collective rise, with the Shanghai Composite Index surpassing 4000 points, indicating positive market sentiment [1] - The Hong Kong Stock Connect innovative drug index increased by 3.85%, with notable individual stock performances such as Zhaoyan New Drug rising over 11% and Tigermed and Kelun-Bio rising over 6% [1] - According to a report by Changjiang Securities, Zhaoyan New Drug is expected to see a 60% year-on-year growth in offshore outsourcing orders in 2024, driven by domestic safety evaluation demand recovery and resource scarcity [1] Group 2 - The China National Medical Products Administration reported that 76 innovative drugs have been approved for market in China by 2025, setting a historical record [1] - The total amount of authorized transactions for innovative drugs in China has exceeded $130 billion, with over 150 transactions, also a historical high [1] - Currently, China's pipeline of new drugs accounts for approximately 30% of the global total, ranking second worldwide [1] Group 3 - The Hong Kong Stock Connect innovative drug ETF managed by Harvest (520970) has a management and custody fee of 0.60% per year, making it suitable for both retail investors as a long-term investment tool and for professional investors seeking flexible trading options [2]

Group 1: Market Performance - The Hong Kong stock market experienced a strong start in 2026, with the Hang Seng Index rising by 2.76% to 26,338.47 points, and the Hang Seng Technology Index increasing by 4% to 5,736.44 points [3] - The Hong Kong Innovation Drug ETF (159570) surged over 5.5%, with a trading volume exceeding 1.6 billion yuan, marking a significant increase compared to the previous trading day [1][3] - As of December 29, 2025, the latest scale of the Hong Kong Innovation Drug ETF reached over 21.4 billion yuan, leading its peers in the same category [1] Group 2: Company News - In a significant development, Insilico Medicine announced a multi-year research collaboration with Servier worth up to $888 million, focusing on oncology drug development [3] - The collaboration will leverage Insilico's AI-driven drug discovery platform, Pharma.AI, in conjunction with Servier's global expertise in oncology [3] - Insilico is eligible for an upfront payment of up to $32 million and milestone payments related to research achievements [3] Group 3: Industry Trends - In 2025, the Chinese innovative drug industry set a record for outbound licensing transactions, with a total transaction value of $135.655 billion and 157 deals, marking a historical high [5] - The industry is witnessing a diversification in business development (BD) models, with an increasing number of innovative drug companies opting for co-development partnerships with multinational pharmaceutical firms [7][10] - The "Co-Co" (Co-development & Co-commercialization) model is emerging as a significant trend in 2025, exemplified by the $11.4 billion deal between Innovent Biologics and Takeda [11]

Group 1 - The pharmaceutical stocks are performing strongly, with notable increases in share prices for companies such as Gilead Sciences-B (up 9.9% to HKD 12.66), Kelun-B (up 6.29% to HKD 427.8), and others [1] - As of January 3, the National Medical Products Administration reported that 76 innovative drugs were approved for market in China in 2025, significantly surpassing the 48 approved in 2024, marking a historical high [1] - The total amount of authorized transactions for innovative drugs in China exceeded USD 130 billion in 2025, with over 150 transactions, also setting a new record [1] Group 2 - The 44th J.P. Morgan Healthcare Conference is scheduled to take place from January 12 to 15, 2026, in San Francisco, expected to attract over 8,000 global participants [2] - This conference, which has been held since 1982, will feature over 500 listed companies and thousands of startups, focusing on deep exchanges around "capital + strategy" [2] - The domestic listed pharmaceutical companies are entering a period of innovation, characterized by a dual-driven model of "independent research and development + overseas business development" [2] - Overall, Chinese pharmaceutical companies are shifting from a "single market-driven" approach to "global value creation," with the JPM conference serving as a key platform for showcasing clinical data and negotiating overseas collaborations [2]

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (520880) has shown significant upward movement, with a peak increase of over 4% and a trading volume exceeding 258 million yuan, surpassing the previous day's total [1]. Group 1: Market Performance - The ETF opened at 0.516, experiencing a rise of 0.018 (3.61%) during trading [1]. - The trading volume reached 2.58 billion yuan, indicating strong market interest [1]. - The ETF has seen a decline of 7.53% over the past 20 days and 17.04% over the past 60 days, reflecting recent market volatility [1]. Group 2: Industry Insights - The National Medical Products Administration reported that 76 innovative drugs were approved for market in China by 2025, significantly exceeding the 48 approved in 2024, marking a historical high [1]. - The total transaction value for innovative drug licensing in 2025 is projected to exceed 130 billion USD, with over 150 licensing transactions, also a record high [1]. Group 3: Investment Strategy - Analysts from Zhongyou Securities suggest that the maturity of clinical data will be a key driver for the innovative drug market in 2026, with business development (BD) becoming a necessary outcome of enhanced competitiveness for domestic new drugs [2]. - The current period is viewed as an optimal configuration window for the Hong Kong Stock Connect innovative drug sector, following a three-month adjustment that began in September 2025 [2]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has unique advantages, including a focus on pure innovative drug companies and a high concentration of leading firms [2][4]. Group 4: ETF Composition - The top ten holdings in the ETF account for over 72% of its weight, showcasing the dominance of leading innovative drug companies [4]. - Notable companies within the ETF include BeiGene (11.51% weight), Innovent Biologics (10.19%), and China National Pharmaceutical Group (9.47%) [4]. Group 5: Alternative Investment Options - For investors seeking to mitigate volatility while still focusing on innovative drugs, the market offers the only ETF (562050) that combines innovative drugs with traditional Chinese medicine, providing a balanced approach [4].

Group 1 - The pharmaceutical stocks are experiencing strong performance, with notable increases in share prices for companies such as Genscript Biotech (up 9.9%), Kelun Biotech (up 6.29%), and others [1] - As of January 3, the National Medical Products Administration reported that 76 innovative drugs have been approved for market in China by 2025, significantly surpassing the 48 approved in 2024, marking a historical high [1] - The total amount of authorized transactions for innovative drugs in China is expected to exceed $130 billion in 2025, with over 150 transactions, also a historical high [1] Group 2 - The 44th J.P. Morgan Healthcare Conference is scheduled to take place from January 12 to 15, 2026, in San Francisco, attracting over 8,000 global participants [2] - This conference will feature more than 500 listed companies and thousands of startups, focusing on deep exchanges around "capital + strategy" [2] - Chinese pharmaceutical companies are entering an innovation harvest period, transitioning from a "single market-driven" model to a "global value creation" approach, with the JPM conference serving as a key platform for showcasing clinical data and negotiating overseas collaborations [2]